The largest life sciences investor in Israel has raised $140 million to invest in ground-breaking pharma and biotechnology companies.
The money is raised by Arkin Holdings and an investor group including Migdal and Phoenix Group and forms its new partnership, Arkin Bio-Ventures II.
The fund, which builds on an earlier fund, aims to invest in ten to twelve private companies developing ground-breaking therapies such as gene therapy, RNA/DNA-based therapy, and targeted therapies for indications with high unmet medical needs.
The new fund will be managed by Pini Orbach, Head of Pharma at Arkin Holdings and Alon Lazarus will be the investment manager of the Fund.
“Inspired by recent scientific breakthroughs, Arkin Bio-Ventures II is well positioned to meaningfully expand its pharma investment capabilities and global reach, to capture innovative technologies and companies that could have a strong impact on medicine and provide new therapies for patients,” said Orbach.